Maraviroc: Perspectives for use in antiretroviral-naive HIV-1-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1087-1096

  Vandekerckhove, Linos ^a,b   Verhofstede, Chris ^b   Vogelaers, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Antiretroviral naive patients; Chemokine receptor antagonist; MERIT

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; VICRIVIROC;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ISCHEMIC HEART DISEASE; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; SIDE EFFECT; VIROGENESIS; VIRUS ENTRY; VIRUS LOAD;

ANTI-HIV AGENTS; CYCLOHEXANES; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIAZOLES;

EID: 65749098603     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp113     Document Type: Editorial

References (48)

1. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296: 827-43.
2. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
3. Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
4. Feng Y, Broder CC, Kennedy PE et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
5. Landovitz RJ, Angel JB, Hoffmann C et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008; 198: 1113-22.
6. Saag M, Prudence I, Heera J et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/ lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study. In: Abstracts of the Fourth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007. Abstract WESS 104.
7. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
8. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007; 370: 81-8.
9. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002; 76: 8953-7.
10. Chan SY, Speck RF, Power C et al. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol 1999; 73: 2350-8.
11. Jensen MA, van't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5: 104-12.
12. Low AJ, Dong W, Chan D et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21: F17-24.
13. Moores A, Thielen A, Dong W et al. Improved detection of X4 virus by V3 genotyping: Application to plasma RNA and proviral DNA. Antivir Ther 2008; 13 Suppl 3: A99.
14. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: Focus on HIV-1. Annu Rev Med 2007; 58: 445-59.
15. Abel S, van der Ryst E, Muirhead GJ et al. Pharmacokinetics of single and multiple oral doses of UK-427,857 - a novel CCR5 antagonist in healthy volunteers. In: Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003. Abstract 547. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Abel S, van der Ryst E, Rosario MC et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1: 5-18.
17. Celsentri Summary of Product Characteristics, Pfizer Ltd, UK. September 2007.
18. Abel S, Russell D, Taylor-Worth RJ et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1: 27-37.
19. Abel S, Jenkins TM, Whitlock LA et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1: 38-46.
20. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-75.
21. Petropoulos C, Limoli K, Whitcomb J et al. Validation studies defining the performance of Monogram's HIV coreceptor tropism assay. In: Abstracts of the Fifth European HIV Drug Resistance Workshop, Cascais, Portugal, 2007. Abstract 57.
22. Saag M, Heera J, Goodrich J et al. Reanalysis of the MERIT study with the enhanced Trofile™ assay (MERIT-ES). In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting, Washington, DC, USA, 2008. Abstract H-1232a. American Society for Microbiology, Washington, DC, USA.
23. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: A meta-analysis of recent clinical trials in treatment-experienced subjects. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2008. Abstract 800. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
24. Van Baelen K, Vandenbroucke I, Rondelez E et al. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J Virol Methods 2007; 146: 61-73.
25. Heera J, Saag M, Ive P et al. Virological correlates associated with treatment failure at week 48 in the Phase 3 study of maraviroc in treatment-naive patients. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2008. Abstract 40LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
26. Briz V, Poveda E, Soriano V. HIV entry inhibitors: Mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57: 619-27.
27. Mori J, Lewis M, Simpson P et al. Characterisation of MVC resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and 2. In: Abstracts of the Sixth European HIV Drug Resistance Workshop, Budapest, Hungary, 2008. Abstract 51.
28. Mori J, Mosley M, Lewis M et al. Characterisation of MVC resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and 2. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, 2007. Abstract 10.
29. Athe MN, Tsibris RP, Chadburn A et al. Lymphoma diagnosis and plasma Epstein-Barr load during vicriviroc therapy: Results of the AIDS Clinical Trials Group 5211. Clin Infect Dis 2009; 48: 642-9.
30. DeJesus E, Walmsley S, Cohen C et al. Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naive HIV-infected patients. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2008. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
31. Law M, Friis-Moller N, Weber R et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003; 4 1-10.
32. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
33. Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIA-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
34. Lundgren JD, Babiker A, El-Sadr W et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197: 1145-55.
35. Verhofstede C, Vandekerckhove L, Eygen VV et al. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009; 50: 126-36.
36. Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: Integration of a new antiretroviral drug class into clinical practice. J Antimicrob Chemother 2008; 61: 1187-90.
37. Lewis M, Simpson P, Xiting L et al. Dual-tropic virus clones from patients enrolled in the MOTIVATE studies, may respond differently in vivo to maraviroc based on their V3 loop sequence. In: Abstracts of the Sixth European HIV Drug Resistance Workshop, Budapest, Hungary, 2008. Abstract 50.
38. Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-8.
39. Choe H, Farzan M, Sun Y et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-48.
40. Kwong PD, Wyatt R, Robinson J et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
41. O'Brien WA, Koyanagi Y, Namazie A et al. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990; 348: 69-73.
42. Rizzuto CD, Wyatt R, Hernandez-Ramos N et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280: 1949-53.
43. Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991; 349: 167-9.
44. Carrillo A, Ratner L. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol 1996; 70: 1310-6.
45. Chesebro B, Wehrly K, Nishio J et al. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992; 66: 6547-54.
46. Cocchi F, DeVico AL, Garzino-Demo A et al. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996; 2: 1244-7.
47. Fouchier RA, Groenink M, Kootstra NA et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66 3183-7.
48. Hwang SS, Boyle TJ, Lyerly HK et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253: 71-4.